Sorvia NKD, Barros DJC, Espino SS

Language: Spanish
References: 18
Page: 501-509
PDF size: 301.72 Kb.

ABSTRACT

Objective: To describe the impact of stage III-IV endometriosis on ovarian reserve markers, number of retrieved oocytes, implantation rate, clinical pregnancy rate, and live birth rate compared to patients without endometriosis.
Materials and Methods: Prospective, analytical cohort study at the Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes between the months of January 2018 and December 2023 in patients in in vitro fertilization protocol or by intracytoplasmic injection. Inclusion criteria: patients diagnosed with stage III-IV endometriosis and endometriomas as the study group and the control group patients with any diagnosis of infertility except stage I-IV endometriosis.
Results: 178 patients with age limits of 25 and 42 years were studied; 89 in the study group and 89 in the control group with any diagnosis of infertility except stage I-IV endometriosis. All patients received in vitro fertilization cycles or intracytoplasmic sperm injection (ICSI). Antimüllerian hormone concentrations (1.6 ± 1.3 vs. 2.5 ± 1.4; p ‹ 0.005) and antral follicle counts (11.4 ± 8.3 vs. 17.5 ± 10.3, p ‹ 0.001) were significantly lower in the stage III-IV endometriosis group. Fewer total follicles (16.2 ± 8.8 vs. 23.1 ± 9.7, p ‹ 0.001) and fewer retrieved oocytes (7.3 ± 5.1 vs. 10.4 ± 4.6, p ‹ 0.001) as well as fewer metaphase II oocytes (6.5 ± 4.7 vs. 8.6 ± 4.2, p 0.003) were found. No reduction in anti-müllerian hormone or antral follicle count was observed in patients with a history of endometrioma or with endometrioma but without surgery. Pregnancy rates were similar in both groups.
Conclusions: Patients with stage III-IV endometriosis undergoing assisted reproductive treatment have decreased ovarian reserve markers and ovarian response to stimulation compared to patients with other causes of infertility. Despite this, pregnancy rates are similar in both groups.

REFERENCES

1. Coccia M, Nardone L, Rizzello F. Endometriosis and Infertility:A Long-Life Approach to Preserve ReproductiveIntegrity. Int J Environ Res Public Health 2022; 19 (0): 6162.https://doi.org/10.3390/ijerph19106162

2. Horne A, Missmer S. Pathophysiology, diagnosis, andmanagement of endometriosis. BMJ 2022; 379: e070750.https://doi.org/10.1136/bmj-2022-070750

3. Vercellini P, Viganò P, Bandini V, Buggio L, et al. Associationof endometriosis and adenomyosis with pregnancy and infertility.Fertil Steril 2023; 119 (5): 727-40. https://www.sciencedirect.com/science/article/pii/S0015028223002273

4. Somigliana E, Li Piani L, Paffoni A, Salmeri N, et al. Endometriosisand IVF treatment outcomes: unpacking theprocess. Reprod Biol Endocrinol 2023; 21 (1): 107. https://doi.org/10.1186/s12958-023-01157-8

5. Nowak-Psiorz I, Ciećwież S, Brodowska A, Andrzej S. Treatmentof ovarian endometrial cysts in the context of recurrenceand fertility. Adv Clin Exp Med 2019; 28 (3): 407-13.https://doi.org/10.17219/acem/90767

6. Al-Fozan H. Tulandi T. Left lateral predisposition of endometriosisand endometrioma. Obstet Gynecol 2003; 101 (1):164-66. https://doi.org/10.1016/s0029-7844(02)02446-8

7. Goyri E, Kohls G, Garcia-Velasco J. IVF stimulation protocolsand outcomes in women with endometriosis. Best PractRes Clin Obstet Gynaecol 2024; 92: 102429. https://doi.org/10.1016/j.bpobgyn.2023.102429

8. de Ziegler D, Pirtea P, Carbonnel M, Poulain M,et al.Assisted reproduction in endometriosis. Best Pract ResClin Endocrinol Metab 2019; 33 (1): 47-59. https://doi.org/10.1016/j.beem.2018.10.001

9. Pacchiarotti A, Frati P, Milazzo G, Catalano A, et al. Evaluationof serum anti-Mullerian hormone levels to assess theovarian reserve in women with severe endometriosis. EurJ Obstet Gynecol Reprod Biol.2014; 172: 62-4. https://doi.org/10.1016/j.ejogrb.2013.10.003

10. Akgul O, Guraslan H, Kovalak E, Karacan T, et al. Associationof endometrioma size with serum anti-mullerian hormone.J Coll Physicians Surg Pak 2022; 32 (9): 1132-36. https://doi.org/10.29271/jcpsp.2022.09.1132

11. Younis J, Shapso N, Ben-Sira Y, Nelson SM, et al. Endometriomasurgery-a systematic review and meta-analysisof the effect on antral follicle count and anti-Müllerianhormone. Am J Obstet Gynecol 2022; 226 (1): 33-51.e7.https://doi.org/10.1016/j.ajog.2021.06.102

12. Tian Z, Zhang Y, Zhang C, Wang Y, et al. Antral follicle countis reduced in the presence of endometriosis: a systematicreview and meta-analysis. Reprod Biomed Online 2021; 42(1): 237-47. https://doi.org/10.1016/j.rbmo.2020.09.014

13. Wu Y, Yang R, Lan J, Lin H, et al. Ovarian endometriomanegatively impacts oocyte quality and quantity but notpregnancy outcomes in women undergoing IVF/ICSItreatment: a retrospective cohort study. Front Endocrinol(Lausanne) 2021; 12: 739228. https://doi.org/10.3389/fendo.2021.739228

14. Yilmaz N, Ceran M, Ugurlu E, Gulerman HC, et al. Impactof endometrioma and bilaterality on IVF / ICSI cyclesin patients with endometriosis. J Gynecol Obstet HumReprod 2021; 50 (3): 101839. https://doi.org/10.1016/j.jogoh.2020.101839

15. Huang X, Sun Z, Yu Q. Impact of endometriosis on embryoquality and endometrial receptivity in women undergoingassisted reproductive technology. Reprod Biol 2023; 23 (2):100733. https://doi.org/10.1016/j.repbio.2023.100733

16. Li A, Zhang J, Kuang Y, Yu C. Analysis of IVF/ICSI-FET Outcomesin women with advanced endometriosis: influenceon ovarian response and oocyte competence. Front Endocrinol(Lausanne) 2020; 11: 427. https://doi.org/10.3389/fendo.2020.00427

17. Hamdan M, Dunselman G, Cheong Y. The impact of endometriomaon IVF/ICSI outcomes: a systematic review andmeta-analysis. Hum Reprod Update 2015; 21 (6): 809-25.https://doi.org/10.1093/humupd/dmv035

18. Rossi A, Prefumo F. The effects of surgery for endometriosison pregnancy outcomes following in vitro fertilization andembryo transfer: a systematic review and meta-analysis.Arch Gynecol Obstet 2016; 294 (3): 647-55. https://doi.org/10.1007/s00404-016-4136-4